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Abstract
Duplication of chromosomal arm 20q occurs in prostate, cervical, colon, gastric, bladder, melanoma, pancreas and breast
cancer, suggesting that 20q amplification may play a causal role in tumorigenesis. According to an alternative view,
chromosomal imbalance is mainly a common side effect of cancer progression. To test whether a specific genomic
aberration might serve as a cancer initiating event, we established an in vitro system that models the evolutionary process
of early stages of prostate tumor formation; normal prostate cells were immortalized by the over-expression of human
telomerase catalytic subunit hTERT, and cultured for 650 days till several transformation hallmarks were observed. Gene
expression patterns were measured and chromosomal aberrations were monitored by spectral karyotype analysis at
different times. Several chromosomal aberrations, in particular duplication of chromosomal arm 20q, occurred early in the
process and were fixed in the cell populations, while other aberrations became extinct shortly after their appearance. A wide
range of bioinformatic tools, applied to our data and to data from several cancer databases, revealed that spontaneous 20q
amplification can promote cancer initiation. Our computational model suggests that 20q amplification induced
deregulation of several specific cancer-related pathways including the MAPK pathway, the p53 pathway and Polycomb
group factors. In addition, activation of Myc, AML, B-Catenin and the ETS family transcription factors was identified as an
important step in cancer development driven by 20q amplification. Finally we identified 13 "cancer initiating genes", located
on 20q13, which were significantly over-expressed in many tumors, with expression levels correlated with tumor grade and
outcome suggesting that these genes induce the malignant process upon 20q amplification.
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Introduction
Impaired genome stability is one of the hallmarks of cancer [1].
Local DNA copy number aberrations have been shown to be
predictive of outcome [2,3,4] or of treatment response [5,6,7] in
several cancers. Although most cancer cells exhibit gain or loss of
chromosomal regions [8], there still is a debate between scientists
whether genomic aberrations are essential for cancer initiation
[9,10] or an outcome of the tumorigenic process [11,12,13]. While
some reports suggest that gain of an extra chromosome exerts anti-
proliferative effects [14,15], others claim that aneuploidy aberra-
tions occur at a premalignant stage [10,16,17,18] resulting in
chromosomal variations and neoplastic phenotype [9].
Several chromosomal duplications have been frequently ob-
served in many types of cancer. Among these, recurrent gain and
amplification of the long arm of chromosome 20 (20q) has been
observed in 90% of pancreatic cell-lines [19], 15–83% of
pancreatic adenocarcinoma [20], around 70% of primary gastric
cancers [21] and of colon cancer [18,22], 50% of ovarian and
cervical and 90% of breast [23] cancers. Gain of the 20q
chromosomal arm was also shown to be a very frequent event at
early stages of prostate carcinogenesis [24,25]. In addition, gain of
the 20q chromosomal region was noticed transiently in early
passage stocks of human mammary fibroblasts, immortalized with
hTERT and SV40 large-tumor oncoprotein [26]. Noticeably, in
almost all these studies 20q is the most frequent amplification, and
deletion of this arm is very rare. Furthermore, several studies show
that amplification of 20q is correlated with poor prognosis [27],
aggressive tumor phenotype, progression [28] and metastasis
formation [19,29,30].
Assessing whether chromosomal imbalances play a causative
role in tumorigenesis, as opposed to being bystanders is a difficult
task. Studies done on clinical samples, of both chromosomal
aberrations and gene expression, are hindered by a variety of
confounding factors, which stem from different genetic back-
grounds of patients, variable and uncharacterized mutations in
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tumors, and the uncontrolled contaminations by inflammatory,
endothelial, and stromal cells. To overcome these obstacles, we
previously established an in vitro transformation model based on
the human lung fibroblasts, WI-38, which gave rise to the
identification of gene expression signatures [31,32,33] associated
with genetic aberrations [34]. In addition, human solid tumors are
usually obtained from resections performed at a time when the
tumor is already fully developed, which excludes the access to
crucial information about tumor initiation and progression.
In order to obtain novel insights into the early stages of
transformation and the genetic networks associated with chromo-
somal abnormalities, we used an in vitro model of prostate cellular
transformation. In this model primary prostate epithelial cells
which were previously immortalized by introducing the catalytic
subunit of telomerase, hTERT (EP156T) [35] were grown in
culture under controlled conditions. The specific aim of this study
was to examine the hypothesis that a particular genomic
aberration occurring at early stage of carcinogenesis is accompa-
nied by changes in gene expression which could serve as a driving
force for tumorigenesis. After 650 days in culture the EP156T
derived cells shared several phenotypic, chromosomal and
transcriptional attributes with prostate cancer samples. We report
herein on two main findings. The first is the prominent and early
role of 20q amplification in the development of our in-vitro cell
culture towards a pre-malignant phenotype, with an enhanced
proliferation rate. Second, we explain the malignant potential of
20q duplication by identifying 13 "cancer initiating genes’’, located
on 20q13, that are over-expressed in several kinds of cancer, and
whose expression is correlated with tumor grade and outcome.
Materials and Methods
Preparation of cell lines
Normal human prostate cells immortalized by telomerase
introduction [35] were grown in culture for 650 days, during
which they were analyzed for cell growth rate, chromosomal
alterations and expression profiling. hTERT elongates chromo-
somal ends preventing replicative senescence of several kinds of
normal human cells [36]. The hTERT immortalized EP156T cells
were designated here as N line (Figure 1). The C, G and M lines
were derived from the N line (Figure 1) after 25 passages
(equivalent to about 150 days). To this end, a mutant of the tumor
suppressor p53 (p53R175H) cloned into a retroviral vector
PLXSN was introduced into the N line. The new cells, stably
expressing the p53R175H mutant, were designated the M line. In
parallel N cells were also infected with the PLXSN vector
containing the GSE56 sequence encoding for a short peptide that
inactivates the p53 tumor suppressor gene in a dominant negative
manner [37], which gave rise to the G line. The empty PLXSN
plasmid was used as a control generating the C line. Oncogenic H-
RasV12 cloned into the pBabe-hygro retroviral plasmid was used
for the infection of C, G and M lines just before passage 80
generating the C8R, the G8R and the M8R cells, respectively.
Additional lines were created by the infection of late passage N
cells with PLXSN plasmid encoding either the p53R175H mutant
(N8M), the GSE56 (N8G) or with the empty plasmid (N8C)
(Figure 1). The infection was followed by maintaining the cells for
two weeks in the presence of 400 mg/ml Neomycin (for cells
infected with the PLXSN vector) or with 50 mg/ml Hygromycin
(for cells infected with the pBabe-hygro vector) in order to select
for the stable expression of the introduced plasmids. The retroviral
infection procedure is detailed in [32]. Growth conditions and
media components are detailed in [35].
Gene expression profiling along the evolution process of
EP156T derived cultures
For gene expression profiling, samples were taken at 32 points
along the cultivation process and hybridized with the GeneChip
Human Genome U133A 2.0 Array (Figure 1). The microarrays
were preprocessed using RMA [38] and normalized. All data is
MIAME compliant; the raw data has been deposited in a GEO
database. The GEO record number is- GSE23038. The 5000
Figure 1. Establishment of the system consisting of four long term cultures. Schematic representation of the main derivative cultures of the
EP156T prostate epithelial cells. Each line stands for the subculture generated in vitro by introduction of specific genetic modifications. The x axis
represents the number of passages in culture (about one week per passage). The chip symbols represent points at which cells were collected and
their RNA hybridized to microarrays; the code for the resulting sample, e.g. G5, represents the line (G) and the approximate number (50) of passages
in culture divided by ten. The chromosome symbol indicates a SKY measurement.
doi:10.1371/journal.pone.0014632.g001
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most varying genes were sorted by the SPIN algorithm [39] and
clustered using SPC [40] to identify 2 main stable clusters of genes
with a correlated pattern of expression.
Spectral Karyotype Analysis (SKY)
Exponentially growing cells were incubated with Colcemid
(0.1 mg/ml) over night, trypsinized, lysed with hypotonic buffer,
and fixed in glacial acetic acid/methanol (1:3). The chromosomes
were simultaneously hybridized with 24 combinatorially labeled
chromosome painting probes and analyzed using the SD200
spectral bioimaging system (Applied Spectral Imaging Ltd.,
Migdal Haemek, Israel).
S-phase analysis
Subconfluent cultures were labeled for one hour with 10 mM
BrdUrd (Sigma). Cells were detached with trypsin, fixed in 70%
ethanol, and treated as follows (PBS washes between each step):
2 M HCl and 0.5% Triton X-100 for 30 min at room
temperature; 0.1 M Na2Br4O7 at pH 8.5; FITC-conjugated anti-
BrdUrd (Becton Dickinson) diluted 1:3 in PBS/1% BSA/0.5%
Tween 20 for 1 hour at room temperature; and finally, 5 mg/ml
propidium iodide and 0.1 mg/ml RNase A. Samples were
analyzed by two-dimensional flow cytometry to detect both
fluorescein and propidium iodide fluorescence using a fluores-
cence-activated cell sorter (FACS) (Becton Dickinson). At least
10,000 cells were analyzed per sample.
Isolation of Total RNA
Total RNA for microarray experiment and for Quantitative Real
Time PCR (QRT-PCR) was isolated using NucleoSpin RNA extract
kit (Macherey-Nagel), according to the manufacturer’s protocol.
Quantitative Real Time PCR (QRT-PCR)
A 2 mg aliquot of the total RNA was reverse transcribed using
MMLV RT (Promega) and random hexamer primers. QRT-PCR
was performed using the SYBR-Green PCR Master Mix reagent
(Applied Biosystems) on an ABI 7300 instrument (Applied
Biosystems). The expression level for each gene was normalized
to that of the GAPDH housekeeping gene in the same sample. The
primers were designed using the Primer Express software. Primer
sequences are available upon request.
The Expression Karyotype
Expression data were used previously to infer chromosomal
aberrations [41,42]. Our working hypothesis is that changes in the
copy number of the DNA of a full chromosome or part of it are
reflected in the gene expression. Deletion of a chromosome causes,
on the average, down regulation in the expression of the genes of
that chromosome, while duplication should be reflected by a
higher expression level. In order to identify chromosomal
imbalances, we compared expression levels of the genes that
reside on each chromosomal arm, in each sample, to a reference
sample of normal cells (N0), and searched for significant
differences in the expression levels. We introduced here a method
for Chromosomal Imbalance Analysis, based on a paired t-test, to
derive chromosomal copy number information from expression
data. The Chromosomal Imbalance Analysis method is described,
tested and compared with a previously derived technique [42] in
the supplementary Text S1, see Figures S1 and S2.
Comparison of the two computational methods with SKY
Two methods have been used to identify "expression karyotype"
in samples. Using the Chromosomal Imbalance Analysis we
calculated, for each sample s, a P-value for each chromosome to
test if the mean difference between the genes in N0, compared to
sample s, is different from zero. The binomial approach [42]
determines whether a significant fraction of the genes on the
chromosome is over-expressed in s versus N0 (or under-expressed).
For details on the differences between the two approaches see
supplementary Text S1.
The results obtained by SKY, which were used to estimate the
predictive power of the two computational methods, were
analyzed as follows. If a chromosomal aberration was observed
in more than 50% of the karyotyped cells, it was considered as a
true aberration; otherwise it was interpreted as noise and removed
from the analysis. Using this definition of the SKY results as the
"ground truth", we compared the performance of the two
computational methods, using receiver operating characteristics
(ROC) analysis (see Figure S2). The performances of the two
methods were similar, and we adopted the Chromosomal
Imbalance Analysis here.
Chromosomal Imbalance Analysis correlation
Denote by Egs the expression level (after log and thresholding) of
probeset g in sample s. For each probeset g in sample s we calculate
DEgs=Egs – Eg,N0. Calculate for each sample s the median of the
DEgs for the significantly changing probeset from 20q (as defined in
the supplementary Text S1 on Chromosomal Imbalance Analysis),
to get Ms. For each probeset g from 20q we calculate the Pearson
correlation between the two sets of numbers: Egs and Ms, and call
this as the Chromosomal Imbalance Analysis correlation of
probeset g (with the expression karyotype of 20q).
Constructing the karyotype evolutionary tree
We constructed a "karyotype evolutionary tree" combining data
from the SKY results and the expression karyotype. The normal
karyotype "species" (46,XY) was the root/ancestor of all the
evolved karyotypes. The tree was constructed manually using the
data from both the expression karyotype and SKY. If the data
from expression karyotype were not consistent with the SKY data
at a specific point, we interpolated the behavior of two adjacent
points, assuming that we were dealing with a continuous process.
Copy number analysis
Ultra-high-resolution Affymetrix Genome-Wide human SNP
arrays 6.0 were used to examine acquired genomic copy number
changes and loss of heterozygosity of EP156T cells. Genomic
DNA was purified using the Tissue DNAkit (Cat.#D3396-02,
EZNA, OMEGA Biotek). DNA prehandling and array hybrid-
ization was performed according to the manufactures instructions
(P/N 702504, Rev3, Affymetrix, Santa Clara, CA), and scanned in
an Affymetrix GeneChip Scanner 3000. Quality control, genotype
calling, probe level normalization and copy number normalization
to produce log2 ratios were made in Affymetrix GeneChipH
Genotyping Console v3.0.1. An in-house reference file generated
from 59 healthy blood donors was used. Data analysis and
visualization was performed in Chromosome analysis suite with a
threshold of minimum 100 kb and 20 markers. Aberrations are
reported according to ICSN nomenclature and NCBI build 36.
Networks and Graphical Representations
Data were analyzed through the use of Ingenuity Pathways
Analysis (IngenuityH Systems, www.ingenuity.com). The network
is a graphical representation of the molecular relationships be-
tween genes/gene products. Genes or gene products are repre-
sented as nodes, and the biological relationship between two nodes
The Oncogenic Potential of 20q
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is represented as an edge (line). All edges are supported by at least
one reference from the literature, from a textbook, or from
canonical information stored in the Ingenuity Pathways Knowl-
edge Base. Human, mouse, and rat orthologs of a gene are stored
as separate objects in the Ingenuity Pathways Knowledge Base,
but are represented as a single node in the network. Nodes are
displayed using various shapes that represent the functional class of
the gene product.
Results
An in vitro model for early prostate carcinogenesis
In order to follow the initial progression stages towards
malignancy in prostate carcinogenesis, we have established a
system based on hTERT-immortalized benign prostate epithelial
(EP156T) cells [35]. These immortalized cells are designated here
as N line. At passage 25, N cells were manipulated to over-express
reagents that inactivate the tumor suppressor p53. To that end,
p53R175H mutant of the tumor suppressor p53 cloned into a
retroviral vector PLXSN was introduced into the N line in parallel
with the GSE56, a p53-inactivating peptide, cloned into the
PLXSN vector, and with an empty PLXSN plasmid as a control.
The four immortalized cell lines including Normal (N), transduced
with GSE56 (G), with mutant- p53R175H (M) and with an empty
vector for control (C) were cultured for an additional 500 days in
vitro. Figure 1 schematically represents this model. Throughout
this manuscript, samples are denoted by LX, where L=N,G,M or
C and the numeral X indicates the number of passages (63) at
which the specific sample was taken, divided by ten (e.g. G4
represent sample taken from the GSE line at passage ,40). Just
before passage 80, oncogenic Ras (H-RasV12) was introduced into
the C, M and G lines yielding C8R, M8R and G8R lines,
respectively as depicted in Figure 1. To this end, the H-RasV12
oncogene cloned into pBabe-Hygro retroviral vector was used.
Additionally, the retroviral reagents described above were used to
over-express the GSE56 and mutant p53R175H in the cells of the
N line at a late passage, generating the N8G, N8M and N8C lines
(Figure 1). A retroviral infection was followed by two weeks of drug
selection to induce stable expression (see Materials and Methods).
To obtain a comprehensive picture of the evolutionary changes
during the prolonged cultivation of cell cultures, we wished to
combine the analyses of cell growth rate, chromosomal alterations
and expression profiling along 650 days in culture of the N, C, G
and M lines. To attain this goal, cells were sampled along this
period and the analyses of cell proliferation, gene expression and
karyotype were performed (Figure 1).
Upon the establishment of our in vitro transformation model, it
was important to evaluate whether this system may represent in-
vivo human cancer in a reliable manner. To that end, we
examined whether along the 650 days of cultivation, the EP156T
cells acquired molecular and phenotypic features typical of actual
tumors. As cellular proliferation is the basic feature of cancerous
transformation, cell growth rate and percentage of proliferating
cells (i. e., cells at the S-phase of the cell cycle), were assessed.
Indeed, an increase in cell growth rate was evident as the cells
cultivation progressed (Figure 2A). In agreement with this, a
higher proportion of proliferating cells was detected at later
passages, as judged by BrdU labeling and FACS analysis
(Figure 2B). Additionally, the expression of the p16INK4a tumor
suppressor gene decreased with time in culture in all four cell lines
(Figure 2C). Reduced levels of p16INK4a are commonly observed
in advanced prostate tumors [43] and were found to be one of the
central events in an in vitro transformation process of human WI-
38 fibroblasts [31,32,33]. Then, we wished to examine whether
the gene expression pattern of EP156T-derived cultures resembles
that of in vivo tumors. To achieve this goal, the following analysis
was conducted. Upon gene expression profiling of the EP156T
cells, a clustering analysis was performed to identify the genes with
correlated expression pattern. The expression patterns of the two
most prominent clusters are presented in Figures 2D and 2E. The
first cluster (Figure 2D) contained 177 transcripts that were up
regulated over time in culture. When examining the Gene
Ontology (GO) enrichment using the David software [44], we
found that these genes were associated with cell proliferation.
Thus, this cluster is termed the "proliferation cluster" along the
manuscript. This trend of expression was validated by QRT-PCR
on three representative genes (Figure S3). The second cluster
(Figure 2E) contained 296 glycoprotein and cell adhesion molecule
transcripts and their expression negatively correlated with the
proliferation cluster. To evaluate whether these changes in gene
expression can be related to the transformation process of EP156T
cells, we examined the expression of the genes of both clusters in a
dataset of 99 samples, obtained from normal prostate, tumor and
metastasis of prostate cancer patients [45]. Strikingly, the
expression of genes of both clusters significantly correlated with
their expression in this set of clinical cancer progression samples
(Figure 2D and 2E, bottom). The finding that, the gene expression
pattern of our in vitro model resembles that of advanced prostate
cancer, suggests that this model recapitulates the molecular events
which occur during in vivo malignant transformation of the
prostate gland. The detailed analysis of these clusters and the
comparison to in vivo data is provided in Text S1. Together, these
observations suggest that during prolonged in vitro culturing of
EP156T prostate immortalized cells, a selection process took place
favoring survival of cells with higher proliferative capacities which
might lead to a transformed phenotype.
Exogenous introduction of telomerase induced the immortali-
zation of EP156T cells due to telomere elongation which was
evident after maintaining the cells for long period in vitro [35].
Furthermore, over-expression of the mutant form of the p53
tumor suppressor and of p53 inactivating peptide GSE56 were
also maintained for long period after their introduction to the cells.
A detailed analysis of the specific functions of mutant p53R175H
over-expressed in EP156T cells is presented in [46]. The retention
of telomerase and altered forms of p53 in EP156T cells over time
suggests that these genes may play a role in the maintenance of
transformation.
20q amplification emerged and dominated the cell
population at early stages of the process
Chromosomal abnormalities. We turned to examine the
chromosomal copy number variations in our cells, as these have
been found to be related to cancer phenotypes. To this end, we
estimated the chromosomal aberration pattern at the population
level using computational analysis of expression data (see
Methods), and on the level of single cells by means of spectral
karyotyping (SKY). We used our data to follow the temporal
evolution of the "expression karyotype"- i.e. the chromosomal
aberrations, as they were reflected in the gene expression pattern.
Our data constitute a real time series, which gives us significant
advantages in identifying the progression of the dominant
chromosomal aberrations.
The "expression karyotype" revealed significant temporal
variation of the expression levels of the genes of several
chromosomal arms for the different lines (Figure 3). Chromosomal
arm 20q showed the most pronounced changes of expression and
was associated with the most significant p-values in all the lines.
When compared to N0, the expression of 20q showed about 1.5
The Oncogenic Potential of 20q
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fold increase in the N line and in the early passages of the M, G
and C lines. Interestingly, in the late passages of the M, G, and C
lines this fold change increased to ,1.8. These results suggest that
cells with a trisomy of 20q dominated the cell population at early
stages of the process, and in the C, G and M lines secondary events
followed and created more than 3 copies of the 20q arm.
Additional aberrations that were observed were amplifications of
9q and 13q in the N line; of 7p, 7q, 18q and, later in the process,
of 3p in the C line; amplification of 9p, 11p and, less significantly,
of 13q in the G line; in the M line we identified, in addition to
amplifications of 13q and 20p, also deletions of 10p and
chromosome 16 (after passage 60).
We performed 24 SKY measurements at different stages of the
process; in each we examined between 4–10 cells (the results are
summarized in Table 1). SKY, in agreement with the expression
karyotype, identified duplication of chromosomes 20, 3, 7, 9, 18
and deletion of 16 along the different lines. In addition,
translocations involving chromosomes 10, 11 and 20 that were
identified by SKY, were recognized as deletions/duplications by
the expression karyotype (as will be discussed below).
At several points the SKY results do not behave according to
our expectations (Table 1). To perform SKY analysis, cells were
defrosted and re-grown at several points rather than using exactly
the same population that was taken for microarrays. Thus founder
effects may be responsible for inconsistencies between different
SKY results (e.g. the duplication of chromosome 7 in passage 41 is
inconsistent with passages 31 and 52) and between SKY and the
expression karyotype observed at some points (e.g. the duplication
of chromosome 18 in the C line or the deletions of chromosomes
13 and 5 in sample N8).
Figure 2. Late passages of EP156T sub cultures exhibit an increased growth pothential and a gene expression pattern resembeling
that of prostate tumors. A. Number of population doublings of EP156T-derived cultures (C, G and M) calculated in 50-day intervals during the 650-
day culture period after hTERT infection, alongside with the number of population doublings performed by non-infected EP156 cells in the first 50
days in culture and the EP156T (N) cells during the next 100 days in culture. B. Percentage of proliferating cells (S-phase) was measured by BrdU
labeling of early passage (C4) and late passage (C8) cells. C. Real time QRT-PCR for p16INK4a expression in the different samples of EP156T system. D.
Top: Expression matrix of a cluster of genes whose expression increased during the transformation process. Within each line samples are ordered
from early to late passages. Lower panel: the mean expression pattern of these genes in samples from prostate cancer patients [45]. The p-value for
the difference in expression between normal and cancer is p = 0.00024 and from normal and cancer to metastasis is p = 0.00013. E. Top: Cluster of
genes containing over-represented glycoprotein and extracellular region genes, the samples for each line are ordered from early to late passages. The
cluster is down-regulated during the transformation process. The lower graph presents the mean expression of the cluster’s genes in cancer samples
[45]. The p-value for the difference in expression between normal and cancer is p = 0.00013 and from normal and cancer to metastasis is p = 0.00023.
doi:10.1371/journal.pone.0014632.g002
The Oncogenic Potential of 20q
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e14632
The karyotype evolutionary tree. To understand better the
evolutionary processes that took place in the course of our
experiment, we constructed a "karyotype evolutionary tree"
(Figure 4) combining data from the SKY results and expression.
Similarly to other evolutionary trees, the "karyotype evolutionary
tree" allows us to understand better which karyotype "species"
emerge, evolve or become extinct during the process. The
evolutionary tree points out the trait (in our case the specific
insertion, deletion or aberration) that gives the selected karyotype
growth advantage over other karyotypes. If the data from the
expression karyotype were not consistent with the data from SKY
analysis at a specific point, we interpolated the behavior of two
adjacent points (see Methods). For example, the SKY results in the
C line showed cells with combinations of additional amplifications
and deletions. Although several possible constructions of the C line
tree were possible, evidence from both the expression karyotype
and from SKY suggested that the most dominant effect in these
cells was duplication of chromosome 7 (at passage 40) followed by
duplication of chromosome 18, which later was followed by
duplication of chromosome 3. On the other hand the expression
karyotype in samples C6 and C7 showed unexpected decrease in
the median fold changes of all the aberrant chromosomes (see
Figure 3). We believe that SKY represents more accurately the
true karyotype at these time points.
The 20q amplification. Early in the process, after about 20
passages, cells that had extra material of 20q – denoted dup(20) –
emerged, and from that point on dominated the cell population. In
addition, three other translocations, all of which involved gain of
additional chromosome 20 material: der(10)t(10;20) (denotes a
derivate of chromosome 10 with additional material from
chromosome 20), der(9)t(9;20;9;11) and der(20)t(20;9) were fixed
in some of the populations and caused changes in gene expression
(see Figure 3 and Figure 4). Contrary to this, we observed that
deletion of chromosome 21 was detected several times along the in
vitro transformation. Interestingly, in all these cases the karyotype
species which contained deletion of 21 became extinct. This
observation suggested that deletion of chromosome 21 was
relatively frequent, but had adverse impact on evolutionary
fitness. From the evolutionary tree it is evident that aberrations
involving the 20q chromosomal arm are the most frequent to be
fixed in the population, resulting in additional copies of genetic
material from this region.
The connection between karyotype and growth rate
The chromosomal imbalance analysis algorithms showed
gradually and statistically significant changes (p-value,0.001
and median |fold| .0.5) in the "karyotype expression" along
the transformation process (Figure 3). The most prominent results
were observed for up regulation of genes encoded by chromosome
20q. Most strikingly, it is seen already in the N2 sample that
corresponds to EP156T culture at passage 22. By SKY analysis,
we validated that chromosome 20 aberrations appeared in N, C,
G and M lines. This suggested that trisomy, partial trisomy or
some other aberration that involved 20q, which occurred in the
beginning of the transformation process, had an evolutionary
advantage and as a result, this chromosomal aberration took over
the entire cell population.
To test the possible linking of chromosomal duplications/
deletions, as measured in our "karyotype expression", to
alterations in the cell proliferation rate, we examined the changes
in cell growth rate and searched for their possible correlation with
any chromosomal aberration. The proliferation rate of EP156T-
derived cells was not steady and exhibited occasional increases and
decreases along the growth progression axis (Figure 2A). Crisis and
selection processes that commonly characterize immortalization
can explain the apparent fluctuations in cell growth rate. The
growth rate instability probably reflects clonal expansion in the
mass culture where clones with different proliferation potentials
Figure 3. Copy number change from expression: results of the (Chromosomal Imbalance Analysis) algorithm. Expression level of each
gene annotated to a particular chromosomal arm was compared to its expression level in the N0 sample (EP156 primary cells at passage 8) that
represents the parental culture of all four lines. For each of the N, C, G and M lines (see text) the upper panel shows the coordinated changes in the
median of the expression of genes annotated to specific chromosomal regions, divided by their median expression in N0. The lower panel is the –log
10(p-value) of the paired t-test between the genes in N0 and the other samples (x-axis) on a specific chromosomal arm. The figure presents the
statistically significant chromosomal arms (p-value,0.001 and median fold change .1.5 or ,0.5 at least at one point).
doi:10.1371/journal.pone.0014632.g003
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exist concomitantly. Thus, we were interested to test whether
acquisition of specific chromosomal aberrations contributed to cell
growth. To this end, we performed correlation analysis between
cell growth rate and gene expression on each chromosomal arm.
The population doubling rate was calculated by counting the cells
at the time point of the expression measurement and 3 days
before. Our analysis indicated that the expression changes of the
genes encoded by chromosomal regions 7q, 13q, 19p and 20q as
derived from our Chromosomal Imbalance Analysis algorithm (see
Methods), were significantly correlated (p,0.05) with the
population-doubling rate (Figure S4). As expected, 20q showed
the highest and most significant (p = 0.001) correlation. Finally, it
was important to validate directly chromosome 20 copy number
alteration. To achieve this, we performed chromosome copy
number analysis of EP156T cells (N cells) at passage 81 utilizing
the ultra-high-resolution Affymetrix Genome-Wide human SNP
arrays 6.0 (Figure 5). This analysis, indeed, demonstrated that the
20q chromosomal region was amplified in the EP156T cells.
Figure 5B demonstrates that these cells contained one extra copy
of the genomic material located between 20q11.22 and 20q13.33,
a region that constitutes almost the entire 20q chromosomal arm.
This direct analysis confirming genomic 20q amplification
validates and supports our conclusions based on SKY and
computational Chromosomal Imbalance Analysis.
Evidence from experiments on another cell type. We
showed previously in a fibroblast in-vitro transformation system,
that hTERT-induced immortalization of WI-38 human diploid
fibroblasts results in the spontaneous emergence of rapidly
proliferating variants (WI-38/Tfast) [32]. Although our previous
karyotype analysis identified only a small translocation between
chromosomes X and 17 [32], we decided to revisit this analysis
using array CGH to search for additional chromosomal
aberrations that might have been undetected previously. We
tested cells from 3 time points along the 650-day-long WI-38
transformation process. For the array CGH we used cells
harvested at a short time after immortalization (passage 34), cells
from passage 70 that on average proliferate at a rate of 0.6 PDLs/
per day, and highly proliferating cells at the end of the process
Table 1. Karyotype analysis of EP156T derived cultures.
Name passage (chip) # cells karyotype
p18 (N2) 4 46,XY,dup(20)
p24 (N2) 4 46,XY dup(20)
p28 8 46,XY,dup(20)
p31 7 46,XY,dup(20)
p41 7 5/47,XY,+7,dup(20); 1/47,XY,+7,+9, dup(20); 1/48,XY,+7,+18,dup(20)
p52 7 6/47,XY,+dup(20); 1/46,XY,+dup(20),221
p58 8 5/47,XY,+9,del(8),der(19)t(8;19),dup(20); 2/46,XY,+9, 221,dup(20); 1/47,XY,+dup(20)
p80 (N8) 6 45–47, XY,+9,der(8)t(8;13),dup(20) In several cells we found del(13) and del(5).
Neo p35 (C4) 8 49,XY,+7,+18,+dup(20)
Neo p39 (C4) 8 2/47,XY,+9,dup(20); 4/47,XY,+7,dup(20); 3/46,XY,+7,221,dup(20); 2/46,XY,dup(20);
Neo p47 (C5) 8 5/47,XY,+7,dup(20); 1/48,XY,+7,+18,dup(20); 1/48,X0,+7,+18,dup(20); 1/47,XY,+7,+18,222,dup(20)
Neo p53 (C5) 5 50,XY,+3,+7,+18,dup(20)
Neo p54 (C5) 6 1/50,XY,+3,+7,+18,dup(20); 1/48,XY,+3,+7,+18,+dup(20),210,221; 1/48,XY,+3,+dup(20)
2/49,XY,+7,+18,dup(20),der(10)t(7;10); 1/49,XY,+3,+7,+dup(20),der(10)t(7;10);
Neo p62 (C6) 9 4/46,XY,dup(20); 5/45,XY,+3,+7,+18,+dup(20)
Neo p74 (C7) 6 5/50,XY, +3,+7,+18,dup(20); 1/49,XY,+3,+7,+18,+dup(20),221
Neo p75 (C7) 7 6/50,XY,+3,+7,+18,dup(20); 1/46,XY, dup(20)
Neo p85 (C8) 9 6/48,XY,+7,+18,dup(20); 3/50,XY,+7,+18,dup(20)+3,+20.
Neo-Ras p82 (C8R) 10 50, XY,+3,+7,+18,dup(20)
GSE p87 (G8) 9 46,XY, der(9)t(9;20;9;11),der(20)t(9;20),dup(20)
GSE-Ras p88 (G8R) 7 46,XY, der(9)t(9;20;9;11),der(20)t(9;20),dup(20)
Mp53 p43 (M4) 7 4/46,XY,dup(20); 1/45,XY,221,dup(20); 1/45,XY,27, dup(20)
1/46,XY,218;der(4)t(4;18)+der(11)t(11;18),dup(20);
Mp53 p54 (M5-6) 8 3/45,XY,216,der(10)t(10;20),dup(20); 1/44,XY,222,216,der(10)t(10;20),dup(20);
1/43,XY,222,216,212,der(10)t(10;20),dup(20); 1/45,X0,der(10)t(10;20),dup(20);
1/44,XY,216,222,Del(3),der(10)t(10;20),der(14)t(3;14),dup(20);
1/45XY,214,216,+7,der(7)t(7;14),der(10)t(10;20),dup(20);
Mp53 p67 (M6-7) 7 4/45,XY,216,der(10)t(10;20),dup(20); 1/44,X0,216,der(10)t(10;20),dup(20)
1/43,X0,216,222,der(10)t(10;20),dup(20); 1/44,XY,216,222,der(10)t(10;20),dup(20)
Mp53 p82 (M8) 4 2/45,XY,216,der(10)t(10;20),dup(20); 1/44,X0,216,der(10)t(10;20),dup(20)
1/84,XX00,22X16,22X18,22X21,2Xder(10)t(10;20),dup(20)
First column contains the identifier of the passage at which the cells were harvested. If expression measurements were performed on the same samples, the symbol for
the array is also indicated. Second column - the number of cells for which SKY analysis was performed. Third column: results of the SKY analysis. +/2 indicate additional
or missing chromosome. "der" denotes a derivative chromosome with translocation (t) from another chromosome (as specified in the parenthesis). "dup" - duplication
of a segment in the chromosome. For example ‘‘220’’ means deletion of chromosome 20, ‘‘20’’ – duplication of chromosome 20 and ‘‘dup20’’ means amplification of
part of chromosome 20.
doi:10.1371/journal.pone.0014632.t001
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(passage 93) that proliferate at 1.1 PDLs/per day on average.
Importantly a careful look reveals a single chromosomal change
that happened at the transition point from slow to fast growing
cells. Increased expression (of about 25%) of the 20q genes was
observed at passage 93 (Figure S5). These data, together with the
high frequency of 20q amplification found in several cell lines
[47,48] and cancers support our assumption that amplification of
20q is a key factor in increasing cell proliferation rate.
A model for cancerous transformation induced by 20q
amplification
The observations made above suggest that the 20q amplification
might have an important role in promoting cancer. In order to
substantiate this claim, we developed a new methodology that
combines data from four sources: our experiment, the Oncomine
database [49], expression data from a study of prostate cancer
patients with full clinical annotation [45] and data from six
different array CGH cancer datasets. We present here a brief
overview and outline (see Figure S6) of our methodology, focusing
on the results of immediate biological relevance; a detailed
explanation of our method can be found in the supplementary
Text S1.
Identifying 13 genes on 20q13 that have high malignant
potential. Our working hypothesis is that one or several genes
from 20q could serve as "cancer initiating genes" and impose
tumorigenic effects on cells when over-expressed as a result of
chromosomal amplification. To determine which genes are most
likely to have this effect we applied several filters on the genes found
on 20q. First we tested which of the genes located on 20q exhibited
altered expression following the chromosomal aberration. We found
132 probesets on 20q, such that their expression was correlated,
probably as a direct outcome, to 20q amplification (see Methods on
Chromosomal Imbalance Analysis correlation and supplementary
Text S1). We referred to these probesets as "primary target genes".
Next, using six independent aCGH data sets [19,21,23,50,51,52]
we identified 20q13 as the region that was most commonly
amplified in cancer. In addition, using expression data from 99
in vivo normal and cancerous prostate samples [45] (see figure S7
and supplementary Text S1) we narrowed down the number of
probesets from 132 to 34. These correspond to 24 "purified primary
Figure 4. Karyotype evolutionary tree. The figure was generated on the basis of the 24 SKY results along the prostate cancer transformation
process and the expression karyotype. Normal prostate human cells (left side of the figure) were used to establish 4 immortalized different lines: GSE,
Control, Normal, and Mutant p53 (see text) that proliferate during 80 passages (x-axis). The chromosome sign denotes a karyotype, its size represents
the percent from the total cells (larger size corresponds to higher percentage) and the colored number (if exists) under the chromosomal sign
corresponds to a new aberration that appears. The dashed arrows represent karyotype "species" that become extinct. Since the SKY was done only on
small numbers of cells and the cells were under selective pressure, in case of a discrepancy between different SKY results along the time line our
assumption is that there is continuity in the cells. That is, an aberration has low probability to disappear and then appear again, rather than being
missed in a single SKY. Similarly to other evolutionary trees, the "karyotype evolutionary tree" allows us to understand better which karyotype
"species" emerge, evolve or become extinct during the process. The evolutionary tree points out the trait (in our case the specific insertion, deletion
or aberration) that gives a particular karyotype growth advantage over others.
doi:10.1371/journal.pone.0014632.g004
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target genes" located on 20q13, correlated with 20q amplification
and were found to be relevant in cancerous prostate samples. We
analyzed (see supplementary Text S1) the expression profile of each
of the 24 "purified primary target genes" (Figure 6) using Oncomine
[49], a compendium of expression data from 25,812 microarrays
measured for 361 cancer data sets. Thirteen out of the 24: UBE2C,
ADRM1, CSE1L, RPN2, C20orf45, MYBL2, TOMM34,
AURKA, RAE1, PFDN4, PSMA7, RPS21 and VAPB showed
exceptionally significant over-expression in several cancers, in
progressed malignant stages (versus early) and in poor (compared to
good) prognosis samples (see Figure S8 for stage, grade and
prognosis and Figure S9 for survival data). We propose that these 13
"cancer initiating genes" are key players in the cancer-driving
processes associated with 20q amplification.
Several Cancer-related pathways are controlled by 20q
Amplification. If our hypothesis that 20q can promote cancer
progression is true, a valid assumption would be that the "cancer
initiating genes" can induce cancer by regulating, directly or
indirectly, several cancer-related pathways. Therefore, we tried to
find hints for the pathways that might be involved in these processes.
As a first step, we tried to identify genes that might be regulated by
genes on 20q. We identified 407 probesets of "secondary target
genes" whose expression levels correlated with 20q amplification but
located off the 20q arm. As such, their expression is also likely to be
influenced indirectly by the amplification of 20q, probably by the
"cancer initiating genes". These 407 probesets can indicate which
processes happened in the cells as a result of the 20q amplification.
So far we did not try to answer either of the following questions:
1. How does over-expression of the "cancer initiating genes" cause
up-regulation of the "secondary target genes"? 2. How does
increased expression of the "secondary target genes" induce cancer
progression? In order to bridge this gap, we performed a very wide
Figure 5. Chromosome copy number analysis (Affymetrix 6.0) of EP156T cells at passage 81. A. Regions of chromosomal gain (blue
arrowheads) and loss (red arrowheads) are mapped onto the different chromosomes and chromosome 20 is highlighted. B. Magnified view of the
regions of chromosomal gain or loss on chromosome 20.
doi:10.1371/journal.pone.0014632.g005
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scale search, using the Oncomine database, to identify which
pathways might have been influenced as a result of the 20q
amplification. We found that genes that changed as a result of
MYC amplification in cancer had a high overlap with our
"secondary target genes" (p-value 10259). In addition, we found
significant overlaps with genes over-expressed as a result of
activities of Mutant p53, MLL and ALL, and with the loss of
activity of Estrogen Receptor, TEL-AML translocation, B-Catenin,
ERBB2 and other "potential regulator genes" that are found in
Table S1, and summarized in Table 2.
To understand better how the "potential regulators" might
promote cancer, we characterized the pathways and networks
which they regulate and to which they belong. GO analysis, using
David software [44], of our "potential regulator genes" found
enrichment of positive or negative regulation of cellular process (p-
value = 2.6E218 and 1.2E214), cell proliferation (p = 2E216),
cell differentiation (2e213), cellular developmental process
(2e213), regulation of apoptosis (2e213). KEGG analysis [53]
of the "potential regulator genes" found the prostate cancer
pathway as the most significant pathway (1.1E-13) in addition to
other cancers like bladder, pancreatic cancer, lung, leukemia and
more (p = 3.6E213 to 2.8E25). Other significantly enriched
KEGG pathways included ERBB (p= 2.6E29), focal adhesion
(p = 4.0E27) and MAPK signaling (p= 1.5E23). Finally we used
Ingenuity Pathway Analysis (IPA) (see Methods) to assign each
"potential regulator gene" to a biological pathway (Figure 7).
Figure 6. Summary of the expression of our 24 "purified primary target genes" in more than 360 experiments of different cancers. The
colors represent the p-value (as calculated by Oncomine) for the significantly over-expressed (red colors) or under–expressed (blue colors) genes in cancer
samples compared to normals. If there are k experiments (represented by the number k in the colored boxes) the colors represent the best of the k
p-values. In the few cases when the gene was over-expressed in some experiments and under-expressed in others in the same kind of cancer, the number
represents the differences between the two; positive numbers meanmore experiments with over-expression, negative numbers - more under-expression.
doi:10.1371/journal.pone.0014632.g006
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Table 2. Cancer related genes associated with 20q amplification.
Genes/Aberrations
# over
-express
# under
-express p-val over p-val under Network
ABL-BCR 1 0 8.9E206 --- RTK
B-Catenin 0 4 --- 6.00E-20 APC
Bcl2 0 1 --- 2.7E218 APOP,p53, FLT3 signaling
BCL6 mutation 0 1 --- 4.7E206
Bmi-1 0 1 --- 3.9E-10 Polycomb
BRAF mutant 1 0 9.6E207 --- RTK
BRCA1 mutant 1 0 1.3E215 --- p53
CEBPA mutant 1 0 4.3E221 ---
c-Src 2 0 5.6E221 --- cytoskeleton
E2F3 0 1 --- 5.6E221 RTK, p53
EED 2 0 --- 2.0E206 Polycomb
EGF 1 2 4.3E211 2.7E218 RTK, EGF pathway
EGFR 1 2 0.0000086 2.7E218 RTK, EGF pathway
ERBB2 (HER2) 1 4 0.0002 2E211 RTK
Estrogen Receptor 1 10 1.1E205 2.7E219
EVI1 0 1 --- 4.2E211 fussion with ETV6 (ETS)
EZH2 2 0 --- 3.5E214 Polycomb
FLI1 6 0 7.6E211 --- ETS
FLT3 1 0 5.3E210 FLT3 signaling
FLT3 Mutation 0 1 3.6E208
HIF-1 0 1 --- 5.1E213 HIF1
IFN-alpha 0 1 --- 6.2E209 Cytokine Network
IL-10 0 3 --- 1.4E215 Cytokine Network
INK4a Deletion 1 0 5.5E205 --- p53
MEK 0 2 --- 7.5E223 RTK, Acitvate ETS
MLL 4 0 4.8E235 --- EGF pathway, FLT3 signaling
Myc 8 0 3.8E259 --- EGF pathway
NF1 1 0 1.9E207 --- RTK
Notch blocking 0 7 --- 9.8E213 p53
p53 3 2 3.1E213 9.8E212 p53
p53 mutant 4 1 3.6E215 4.3E206 p53
PAX3-FKHR 0 1 --- 3.5E206
PIK3CA mutant 0 1 --- 8.3E207 PI3K
PLZF/RAR 0 1 --- 4.3E235
PML/RAR 0 1 --- 0.0000016
PTEN 0 2 --- 0.000018 PI3K
Raf 0 2 --- 0.0000043 RTK FLT3 signaling
RELA 0 1 0.000034 --- EGF pathway
SDHB 1 0 3.6E208 --- HIF1
SUZ12 2 0 --- 0.000036 Polycomb
SV40 2 0 7.5E220 ---
TCF3/PBX1 1 0 0.0000023 ---
TEL-AML 0 5 --- 1.1E231
VHL 0 1 --- 2.6E212 HIF1
Vitamin D 0 1 --- 2.9E233
First column – list of "potential regulators". Second/third columns: the number of concepts that were over-expressed/under-expressed in the comparisons that defined
the corresponding Oncomine concept. Each listed concept is associated with a "potential regulator" gene, and has a statistically significant overlap with the list of
"secondary target genes". Columns four/five present the corresponding p-values (if more than one concept was based on a "potential regulator", the best p-value was
cited). The last column shows the network to which the "potential regulator" belongs, as identified by [13].
doi:10.1371/journal.pone.0014632.t002
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In order to produce a model for cancerogenesis induced by 20q
amplification, we searched for known interactions between our
"cancer initiating genes" and "potential regulator genes". We tried
to identify transcription factors that were involved in the process
and, finally, to connect all the components ("cancer initiating
genes", "potential regulator genes" and transcription factors) to
cancer related pathways. Promoter analysis of the "secondary
target genes" using the POC software [54] identified a list of
transcription factors. The most significant motifs that were found
in our analysis were the ETS family transcription factors (like
ELK1, FLI1 and others) and HIF1. Note that both HIF1 and ETS
family transcription factors, also belong to our "potential regulator
genes". In addition we found several significant (FDR 0.01) cell
cycle related transcription factors like E2F, NFY and CDE, and
few more motifs (see Table S2) in the promoters of the "secondary
target genes". The lists of "cancer initiating genes", "potential
regulator genes" and transcription factors were processed using the
Ingenuity Pathway Analysis (IPA), scanning for known biological
connections between the members of the lists (see Methods).
Figure 7 summarizes the known regulatory interactions of "cancer
initiating genes" with the "potential regulator genes" and
transcription factors (blue arrows). If no direct connections were
found, we searched for indirect connection through mediator
genes, and if several such genes where found, we connected
representative interactions (green arrows). Finally, we connected
the genes in the lists to known pathways, based on the IPA
database.
Discussion
This study presents a detailed description and analysis of the
changes in genome-wide expression and chromosomal karyotype,
followed in the course of a unique 650-day long in vitro process,
which transformed normal prostate cells into pre-cancer-like
phenotypes. Chromosomal aberrations were identified in two
independent complementary ways: directly, by SKY and indirect-
ly, from gene expression data. Furthermore, we confirmed 20q
amplification, the central chromosomal aberration in this system,
by high resolution DNA copy number analysis using SNP arrays.
We introduced and applied a novel approach to determine which
biologically relevant networks were involved in the cancerous
transformation process. To do this, we used extensive data from
more then 300 previously published experiments from several data
bases and a wide variety of bioinformatic tools.
Based on our results, we propose the following model for cancer
initiation driven by 20q amplification (Figure 7): 1. Spontaneous
amplification of 20q occurred in a subclone of cells and caused up-
regulation of large group of genes located on this chromosomal
arm. We identified 13 out of the 600 genes on chromosome 20 as
those with high oncogenic potential. 2. The high expression levels
of these genes caused direct and indirect changes in the activities of
various transcription factors and oncogenic pathways. 3. The
activation of those pathways and transcription factors caused
increased activity of the cell cycle, metabolic and ribosomal
pathways, and down-regulation of cell adhesion associated genes.
These modifications of the cells’ expression profile may have
caused higher proliferation rate and loss of contact inhibition in
early stages, progression of cancer, bad prognosis and aggressive-
ness in later stages. Indeed when we and others examine the
expression pattern of 20q genes, and, in particular, of our 13
"cancer initiating genes" in different tumors, we find significant
correlation with progression, tumor grade and outcome.
Our in-vitro model provided us a unique opportunity to
monitor continuously the spontaneous evolutionary changes that
happened during the 650 days of culture following immortaliza-
tion. We established the amplification of chromosomal arm 20q as
a key initiating event in early cancer formation. We identified 13
genes, located at the 20q13 chromosomal region, which are likely
key players, driving progression in many cancers. Furthermore,
our study suggests possible mechanisms through which amplifica-
Figure 7. Cancer transformation model. Using Ingenuity Pathway Analysis (IPA, see Methods), we summarized the known regulatory interaction
of "cancer initiating genes" with the "potential regulator genes" and transcription factors (blue arrows). When no direct connection was found, we
searched for indirect connections through mediator genes. If more than one such gene was found, we connected representative interactions (green
arrow). Finally, we connected the genes in the lists to known cancer related pathways, based on the IPA database. First row: the list of "cancer
initiating genes" which are located on 20q13. Second row: mediators - genes that have protein-protein interaction with the "cancer initiating genes"
or are regulated by these genes and are also known regulators of the "potential regulator genes". Third row: The transcription factors that were found
by POC. 4th row: the "potential regulator genes". 5th row: the list of cancer pathways as defined by IPA and the "potential regulator genes" from our
analysis that belong to these pathways. We filtered out the"potential regulator genes" and transcription factors for which no direct or through one
mediator connection to our "cancer initiating genes" were found.
doi:10.1371/journal.pone.0014632.g007
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tion of an entire chromosomal region induces the cancerous
transformation, providing clues that might explain why 20q
amplification is one of the most common genetic aberrations in
cancer.
Some previously identified potential oncogenes [55,56] that also
reside on 20q13 were not included: EEF1A2, PTPN1, and
ZNF217 did not pass our filters. A possible reason for this might be
that our primary filters were based on prostate cells; and unequal
representation of different cancer studies in the Oncomine
database that we used.
It will be important to further investigate and validate the
crosstalk between the 13 genes on 20q13 and each of the suggested
networks. It will be interesting to apply our method to other
common chromosomal aberrations like 18q or 13q amplifications,
but it is not clear whether a similar system can be found in which
one of these amplifications is the central early alteration.
Different types of human cells might require either similar or
different clonal markers of transformation. Interestingly, human
fibroblasts immortalized by hTERT and the oncogenic sequences
of the SV40 virus exhibited a transient gain of the genetic material
from the chromosomal arm 20q [26] while the hTERT-
immortalized EP156T cells demonstrated stable 20q amplification.
This might suggest that the amplification of the 20q chromosomal
region in the fibroblast cells containing SV40 large tumor
oncoprotein was important for the transition point at which
normal cells become immortal serving as an initiating event. The
difference between these cells and our immortalized EP156T cells
is that the immortalized fibroblasts contain SV40 large tumor
oncoprotein and represent fibroblastic cells while our immortal-
ized culture does not contain SV40 sequences and represents cells
from epithelial origin. For these reasons EP156T cells may depend
on the 20q amplification for their immortalized status.
In conclusion, we showed that 20q amplification occurred early
in the transformation process and had a strong evolutionary
advantage in the cell population. We proposed a model that
explains the main routes through which 20q amplification may
induce tumor initiation. Additionally, we suggested several
potential oncogenes that might be key factors in this process. We
believe that our work is an important step in understanding cancer
initiation and progression and may give rise to new therapeutic
possibilities by targeting the cause or the consequences of specific
chromosomal aberrations.
Supporting Information
Figure S1 Using our gene expression data we applied paired t-
test to predict chromosomal aberration in all chromosomal arms
in the 27 samples. The analysis was done using varying number of
genes, from all (12000 unique genes) to the 1000 most variable
genes. The results showed that using the 7500 to 5500 most
variable genes (black box) maximizes for the number of predicted
chromosomal duplications/deletions. This result does not depen-
dent on the p-value that we chose as threshold.
Found at: doi:10.1371/journal.pone.0014632.s001 (8.76 MB TIF)
Figure S2 ROC curves for the two methods. The x-axis
represents the false-positives rate, and the y-axis represents the
true-positives rate of the two methods, when compared to the SKY
results.
Found at: doi:10.1371/journal.pone.0014632.s002 (4.40 MB TIF)
Figure S3 QRT-PCR validation in proliferation cluster genes:
BUB1 TPX2 and MYBL2 at progressive time points along the
long term in vitro culture.
Found at: doi:10.1371/journal.pone.0014632.s003 (3.01 MB TIF)
Figure S4 Pearson correlation between the growth rate and
the expression of genes on each indicated chromosomal arm.
* p-value,0.05, ** p-value,0.001 for up regulation of genes
encoded by this region.
Found at: doi:10.1371/journal.pone.0014632.s004 (0.69 MB TIF)
Figure S5 Raw array CGH data for WI-38 human diploid
fibroblast cells obtained from passage 93 in an in-vitro transfor-
mation experiment (Milyavsky et al. 2005). Around 25% percent
of the cells contained amplification of chromosome 20.
Found at: doi:10.1371/journal.pone.0014632.s005 (0.24 MB TIF)
Figure S6 Workflow of our analysis of the tumorigenic effect of
20q amplification. The colors represent four different data types that
were used: Oncomine (green), our prostate in-vitro transformation
model (red), prostate samples from patients (blue) and array CGH
data (black). Each box represents a step in the analysis. The arrows
indicate that information was passed from one box to another.
Found at: doi:10.1371/journal.pone.0014632.s006 (0.09 MB TIF)
Figure S7 Expression pattern of 20q genes in normal and
cancerous prostate samples. Median Expression pattern (after
normalization and log2) of genes in 99 in-vivo normal and
cancerous prostate samples (Glinsky et al. 2004) at different stages
of progression, as indicated by the color bar (blue for normal
prostate, orange for primary tumor, red for metastatic tissue). A.
Median expression of our "primary target genes". The blue dots
mark samples which we predict to have 20q amplification B.
Median expression of the "secondary target genes". C. Median
expression of the genes encoded by the 20p chromosomal region.
D. Median expression of the 20q genes which were not identified
as "primary target genes" (not correlated with our 20q expression
karyotype).
Found at: doi:10.1371/journal.pone.0014632.s007 (2.91 MB TIF)
Figure S8 Summary of the expression of our 24 "purified
primary target genes" in more than 360 experiments of different
cancers. The colors represent the p-value (as calculated by
Oncomine) for significant over-expression (red colors) or under-
expression (blue colors) in different grade, stage or prognosis of
each single "purified primary target genes". If there are several
experiments (denoted by the number in the corresponding box)
the color represents the best p-value from these experiments.
Found at: doi:10.1371/journal.pone.0014632.s008 (8.32 MB TIF)
Figure S9 Survival and relapse test for our "cancer initiating
genes" in several data sets. The figure shows genes whose
expression levels (high 50% vs. low) significantly differentiate
cancer patients by survival and relapse in several studies
Found at: doi:10.1371/journal.pone.0014632.s009 (4.81 MB TIF)
Table S1 Oncomine Concepts with significant overlap with the
"secondary target genes"
Found at: doi:10.1371/journal.pone.0014632.s010 (0.14 MB
XLS)
Table S2 List of over represented motifs (that pass FDR of 0.01)
in the "secondary target genes" promoters. We ran promoter
analysis on the two "secondary target genes" groups (that passed
the filters R.0.7 and R.0.6, see text). (R.0.6) denotes that the
motif was found only when we used correlation R.0.6. Conserved
in mouse - The motif is conserved in the mouse promoters
Found at: doi:10.1371/journal.pone.0014632.s011 (0.04 MB
XLS)
Text S1 Supplementary information
Found at: doi:10.1371/journal.pone.0014632.s012 (0.16 MB
DOC)
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